BACKGROUND AIMS: Modified vaccinia Ankara (MVA) is a promising vaccine vector for infectious diseases and malignancies. It is fundamental to ascertain its tropism in human leukocyte populations and immunostimulatory mechanisms for application in immunotherapy. METHODS: Human peripheral blood mononuclear cells (PBMC) and leukocyte subpopulations [monocyte-derived dendritic cells (DC), monocytes and B cells] were infected with MVA in order to evaluate their infection rate, changes in surface markers, cytokine expression and apoptosis. RESULTS: Monocytes, DC and B cells were most susceptible to MVA infection, followed by natural killer (NK) cells. Monocytes were activated strongly, with upregulation of co-stimulatory molecules, major histocompatibility complex (MHC) molecules and chemokine (C-C motif) receptor (CCR7), while immature DC showed partial activation and B cells were inhibited. Furthermore, expression of chemokine (C-X-C motif) ligand (CXCL10), tumor necrosis factor (TNF)-α, interleukin (IL)-6 and IL-12p70 was enhanced but IL-1β and IL-10 were stable or even downregulated. MVA induced a high apoptosis rate of antigen-presenting cells (APC). Nevertheless, incubation of MVA-infected leukocytes with uninfected immature DC (iDC) led to complete maturation of the DC. Subsequently, the matured DC were able to stimulate cytomegalovirus (CMV)-immediate early protein (IE1)-specific T cells. CONCLUSIONS: MVA induces a T-helper (Th)-1-polarizing cytokine expression in APC. Furthermore, incubation of MVA-infected leukocytes with uninfected iDC leads to complete maturation of the DC and may be the basis for cross-presentation of MVA-encoded antigens. Thus this approach seems to be an ideal model for further studies with MVA-encoded viral antigens regarding immunotherapy and vaccination strategies.
BACKGROUND AIMS: Modified vaccinia Ankara (MVA) is a promising vaccine vector for infectious diseases and malignancies. It is fundamental to ascertain its tropism in human leukocyte populations and immunostimulatory mechanisms for application in immunotherapy. METHODS:Human peripheral blood mononuclear cells (PBMC) and leukocyte subpopulations [monocyte-derived dendritic cells (DC), monocytes and B cells] were infected with MVA in order to evaluate their infection rate, changes in surface markers, cytokine expression and apoptosis. RESULTS: Monocytes, DC and B cells were most susceptible to MVA infection, followed by natural killer (NK) cells. Monocytes were activated strongly, with upregulation of co-stimulatory molecules, major histocompatibility complex (MHC) molecules and chemokine (C-C motif) receptor (CCR7), while immature DC showed partial activation and B cells were inhibited. Furthermore, expression of chemokine (C-X-C motif) ligand (CXCL10), tumor necrosis factor (TNF)-α, interleukin (IL)-6 and IL-12p70 was enhanced but IL-1β and IL-10 were stable or even downregulated. MVA induced a high apoptosis rate of antigen-presenting cells (APC). Nevertheless, incubation of MVA-infected leukocytes with uninfected immature DC (iDC) led to complete maturation of the DC. Subsequently, the matured DC were able to stimulate cytomegalovirus (CMV)-immediate early protein (IE1)-specific T cells. CONCLUSIONS: MVA induces a T-helper (Th)-1-polarizing cytokine expression in APC. Furthermore, incubation of MVA-infected leukocytes with uninfected iDC leads to complete maturation of the DC and may be the basis for cross-presentation of MVA-encoded antigens. Thus this approach seems to be an ideal model for further studies with MVA-encoded viral antigens regarding immunotherapy and vaccination strategies.
Authors: E Guzman; C Cubillos-Zapata; M G Cottingham; S C Gilbert; H Prentice; B Charleston; J C Hope Journal: J Virol Date: 2012-03-14 Impact factor: 5.103
Authors: Philip J R Price; Bruno Luckow; Lino E Torres-Domínguez; Christine Brandmüller; Julia Zorn; Carsten J Kirschning; Gerd Sutter; Michael H Lehmann Journal: J Virol Date: 2014-07-09 Impact factor: 5.103
Authors: Arwen F Altenburg; Carolien E van de Sandt; Bobby W S Li; Ronan J MacLoughlin; Ron A M Fouchier; Geert van Amerongen; Asisa Volz; Rudi W Hendriks; Rik L de Swart; Gerd Sutter; Guus F Rimmelzwaan; Rory D de Vries Journal: Sci Rep Date: 2017-08-17 Impact factor: 4.379
Authors: Pierre Rosenbaum; Nicolas Tchitchek; Candie Joly; Lev Stimmer; Hakim Hocini; Nathalie Dereuddre-Bosquet; Anne-Sophie Beignon; Catherine Chapon; Yves Levy; Roger Le Grand; Frédéric Martinon Journal: Front Immunol Date: 2018-04-25 Impact factor: 7.561
Authors: Jessamine E Hazlewood; Troy Dumenil; Thuy T Le; Andrii Slonchak; Stephen H Kazakoff; Ann-Marie Patch; Lesley-Ann Gray; Paul M Howley; Liang Liu; John D Hayball; Kexin Yan; Daniel J Rawle; Natalie A Prow; Andreas Suhrbier Journal: PLoS Pathog Date: 2021-01-13 Impact factor: 6.823
Authors: Hannah R Sharpe; Nicholas M Provine; Georgina S Bowyer; Pedro Moreira Folegatti; Sandra Belij-Rammerstorfer; Amy Flaxman; Rebecca Makinson; Adrian Vs Hill; Katie J Ewer; Andrew J Pollard; Paul Klenerman; Sarah Gilbert; Teresa Lambe Journal: JCI Insight Date: 2022-03-22
Authors: Beatriz Perdiguero; Carmen Elena Gómez; Jose Luis Nájera; Carlos Oscar S Sorzano; Julie Delaloye; Rubén González-Sanz; Victoria Jiménez; Thierry Roger; Thierry Calandra; Giuseppe Pantaleo; Mariano Esteban Journal: PLoS One Date: 2012-10-31 Impact factor: 3.240
Authors: José I Quetglas; Liza B John; Michael H Kershaw; Luis Alvarez-Vallina; Ignacio Melero; Phillip K Darcy; Cristian Smerdou Journal: Oncoimmunology Date: 2012-11-01 Impact factor: 8.110